{"id":"gsk3511294","safety":{"commonSideEffects":[{"rate":null,"effect":"Upper respiratory tract infection"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nasopharyngitis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"TYK2 is a non-receptor tyrosine kinase that plays a critical role in type I and type III interferon signaling and IL-23 signaling. By selectively inhibiting TYK2, GSK3511294 reduces the activation and differentiation of pro-inflammatory T cells and other immune cells, thereby dampening pathogenic immune responses in autoimmune and inflammatory conditions.","oneSentence":"GSK3511294 is a selective inhibitor of TYK2 (tyrosine kinase 2) that suppresses inflammatory signaling pathways involved in immune-mediated diseases.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:14:44.150Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Psoriasis"},{"name":"Inflammatory bowel disease"}]},"trialDetails":[{"nctId":"NCT07456033","phase":"PHASE3","title":"A Study of Efficacy and Safety of Depemokimab Compared With Placebo in Adults and Adolescents With at Risk Type 2 Asthma","status":"NOT_YET_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2026-03-06","conditions":"Asthma","enrollment":456},{"nctId":"NCT05243680","phase":"PHASE3","title":"An Open-Label Extension Study of GSK3511294 (Depemokimab) in Participants Who Were Previously Enrolled in 206713 (NCT04719832) or 213744 (NCT04718103)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2022-03-01","conditions":"Asthma","enrollment":641},{"nctId":"NCT05274750","phase":"PHASE3","title":"Efficacy and Safety of Depemokimab (GSK3511294) in Participants With Chronic Rhinosinusitis With Nasal Polyps","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2022-04-22","conditions":"Nasal Polyps","enrollment":276},{"nctId":"NCT04718389","phase":"PHASE3","title":"A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2021-01-26","conditions":"Asthma","enrollment":1719},{"nctId":"NCT06959095","phase":"PHASE3","title":"Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA -1)","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2025-06-20","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":981},{"nctId":"NCT05281523","phase":"PHASE3","title":"Efficacy and Safety of Depemokimab (GSK3511294) in Participants With Chronic Rhinosinusitis With Nasal Polyps (ANCHOR-2)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2022-04-18","conditions":"Nasal Polyps","enrollment":264},{"nctId":"NCT06961214","phase":"PHASE3","title":"Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2025-06-23","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":960},{"nctId":"NCT05140200","phase":"PHASE1","title":"Study of GSK3511294 in Healthy Chinese Participants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2021-12-10","conditions":"Asthma","enrollment":20},{"nctId":"NCT04719832","phase":"PHASE3","title":"Placebo-controlled Efficacy and Safety Study of GSK3511294 (Depemokimab) in Participants With Severe Asthma With an Eosinophilic Phenotype","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2021-03-17","conditions":"Asthma","enrollment":395},{"nctId":"NCT04718103","phase":"PHASE3","title":"A Study of GSK3511294 (Depemokimab) in Participants With Severe Asthma With an Eosinophilic Phenotype","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2021-02-04","conditions":"Asthma","enrollment":397},{"nctId":"NCT03287310","phase":"PHASE1","title":"First Time in Human (FTIH) Study to Evaluate Safety, Tolerability, Immunogenicity, Pharmacokinetics (PK) and Pharmacodynamics (PD) of GSK3511294 Administered Subcutaneously (SC) in Subjects With Mild to Moderate Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2017-10-17","conditions":"Asthma","enrollment":50}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Depemokimab"],"phase":"phase_3","status":"active","brandName":"GSK3511294","genericName":"GSK3511294","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Small molecule","firstApprovalDate":"","aiSummary":"GSK3511294, also known as Depemokimab, is an interleukin-5 inhibitor, a type of antibody that targets Interleukin-5. It is being studied in clinical trials for conditions such as asthma, nasal polyps, pulmonary disease, and chronic obstructive pulmonary disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}